TAVANIC

levofloxacin

1
Mode Of Action

Rapid bactericidal action:

inhibits DNA gyrase (resealing)

inhibits topoisomerase IV

(no separation of interlinked daughter DNA molecules)

2
Pharmacokinetics
Rapid, complete absorption after oral administration

100% bioavailable

T-max : 1 hour

IV and oral formulations are bioequivalent switch /

sequential therapy

Minimal hepatic metabolism; 2 metabolites identified in

urine (<5% of total Levofloxacin)

Half life is 6 8 hours

once daily dosage

3
Indications
a) Upper respiratory tract infections
sinusitis due to:

GRAM-POSITIVE GRAM-NEGATIVE

*
M. catarrhalis **
S. pneumoniae
H. influenzae ***
S. aureus ***
H. parainfluenzae

* -lactamase producers
** intraphagocytic

6
Indications (Cont)
b) Lower respiratory tract infections:
acute exacerbation of chronic bronchitis (AECB) due to:

GRAM-POSITIVE GRAM-NEGATIVE
*
M. catarrhalis **
H. influenzae ***
S. pneumoniae
H. parainfluenzae
S. aureus ***
K. pneumoniae*
E. coli*
* -lactamase producers
** intraphagocytic

7
Indications (Cont)
c) Lower respiratory tract infections (cont):
Community acquired pneumonia (CAP) due to:

GRAM- GRAM- ATYPICAL

POSITIVE NEGATIVE BACTERIA
S. pneumoniae M. catarrhalis*** M. pneumoniae ***
* *
S. aureus ** H. influenzae ** C. pneumoniae ***
H. parainfluenzae L. pneumophila ***
K. pneumoniae*
E. coli*
* -lactamase producers
** intraphagocytic
*** intracellular
8
Indications (Cont)
e) Skin and soft tissue infections:
uncomplicated infections such as abscess, cellulitis, carbuncles,
impetigo due to:

GRAM-POSITIVE GRAM-NEGATIVE
Acinitobacter
Enterobacter
S. aureus **
P. mirabilis
S. pyogenes
P. aeruginosa
S. faecalis
E. coli*
K. pneumoniae*
* -lactamase producers
** intra-phagocytic
10
Indications (Cont)
f) Complicated skin and soft tissue infections
such as diabetic foot ulcers, pressure sores, traumatic and post-
surgical wound infections due to:

GRAM-POSITIVE GRAM-NEGATIVE
P. mirabilis
S. aureus* E. coli*
S. pyogenes K. pneumoniae*
S. faecalis Enterobacter
K. oxytoca
* -lactamase producers
** intra-phagocytic

11
 Dosage
500mg once daily, which enhances patient
compliance.

Bioequivalent Oral or IV , allows for switch

therapy.

Dosage and duration depends on the type and

severity of infection.

Continue for a further 48 - 72 hours after patient

is afebrile or evidence of bacteriological
eradication.

13
14
15